Hims & Hers Health, Inc. (NYSE:HIMS) Position Cut by Mackenzie Financial Corp

Mackenzie Financial Corp lowered its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 2.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,684 shares of the company’s stock after selling 650 shares during the period. Mackenzie Financial Corp’s holdings in Hims & Hers Health were worth $458,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in HIMS. Nisa Investment Advisors LLC raised its stake in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares in the last quarter. Quest Partners LLC raised its position in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after buying an additional 3,507 shares in the last quarter. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health in the 2nd quarter worth approximately $111,000. Belpointe Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after acquiring an additional 1,205 shares in the last quarter. Finally, Amalgamated Bank increased its stake in shares of Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 3.1 %

Shares of HIMS stock opened at $17.66 on Friday. The company has a market capitalization of $3.79 billion, a price-to-earnings ratio of -1,766.00 and a beta of 1.06. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $25.74. The stock’s fifty day simple moving average is $16.54 and its 200-day simple moving average is $17.28.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business’s revenue for the quarter was up 51.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.03) EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Truist Financial raised their target price on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Jefferies Financial Group boosted their price target on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. Piper Sandler reaffirmed a “neutral” rating and issued a $18.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Finally, Bank of America cut their target price on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, September 13th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and an average price target of $19.86.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,335 shares of the stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $20.28, for a total transaction of $47,353.80. Following the completion of the sale, the insider now directly owns 169,144 shares in the company, valued at approximately $3,430,240.32. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Soleil Boughton sold 2,335 shares of the stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $20.28, for a total value of $47,353.80. Following the transaction, the insider now owns 169,144 shares in the company, valued at approximately $3,430,240.32. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Oluyemi Okupe sold 11,609 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40. Following the transaction, the chief financial officer now directly owns 181,469 shares in the company, valued at approximately $2,649,447.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 524,960 shares of company stock valued at $8,390,362 in the last quarter. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.